RXRX today
$3.19-$0.15 (-4.35%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minLeaning Bullish
5 minLeaning Bearish
Daily trend turns up above $5.19
Key levels
Resistance$4.09
Resistance$3.44
Support$2.92
Latest news & SEC filings
No headlines in the last 90 days.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses an AI-driven platform, the Recursion Operating System, to discover and develop small molecule drugs. Its internal pipeline targets oncology and rare diseases, with lead programs in familial adenomatous polyposis and advanced solid tumors. The company also partners with large pharmaceutical firms such as Roche, Genentech, Sanofi, Bayer, and Merck KGaA on drug discovery programs. It operates primarily in the United States.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
RECURSION PHARMACEUTICALS, INC. (RXRX)
What Is the Price Target for RXRX?
SEPT Low Target
$6.80
SEPT Mid Target
$8.00
SEPT High Target
$9.20
Analyst Consensus
$8.00
Is RXRX a Buy or Sell Right Now?
Thesis
- •Revenue growing 26.9% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RXRX.
Start Free Trial →Is RXRX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$7.02
25
Moat Score
NONE
4/9
Piotroski Score
0.3
Altman Z-Score
What Is Smart Money Doing with RXRX?
Insider Signal
SELLING
0 buys / 11 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Borgeson Blake | director | Sale | 40,000 | $155K | Nov 3, 2026 |
| Hassan Fred | director | Buy | 156,658 | - | Nov 2, 2026 |
| HERSHBERG ROBERT | director | Buy | 25,000 | $56K | Oct 6, 2026 |
| HERSHBERG ROBERT | director | Sale | 25,000 | $125K | Oct 6, 2026 |
| Borgeson Blake | director | Sale | 50,000 | $242K | Oct 6, 2026 |
| Khan Najat | director officer | Sale | 22,408 | $79K | Sep 8, 2026 |
| Borgeson Blake | director | Sale | 30,000 | $100K | Sep 1, 2026 |
| Khan Najat | director officer | Sale | 23,588 | $84K | Jun 5, 2026 |
| Gibson Christopher | director | Buy | 40,000 | - | Jun 5, 2026 |
| Gibson Christopher | director | Sale | 40,000 | $145K | Jun 5, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RXRX Growth Story
Revenue YoY
26.9%
3yr Revenue CAGR
23.3%
EPS Growth YoY
14.79%
FCF Growth YoY
-1.4%
Revenue Trend
ACCELERATING
Dark Pool Trades for RXRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RXRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 24:53:50 | $3.16 | 7,800 | $$25K | SELL |
| 24:53:45 | $3.16 | 1,083 | $$3K | SELL |
| 24:43:10 | $3.17 | 5,100 | $$16K | BUY |
| 24:43:10 | $3.17 | 4,000 | $$13K | BUY |
| 24:24:46 | $3.16 | 1,200 | $$4K | SELL |
5 dark pool trades shown · $$61K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for RXRX
PREVIEWSEPT Investing provides real-time options flow tracking for RXRX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $4 | Jan 15 | 63 | $$1275 | 51 | SWEEP |
| CALL | $4 | Jan 15 | 63 | $$350 | 14 | SWEEP |
| CALL | $5 | Jan 21 | 434 | $$400 | 5 | SWEEP |
| CALL | $5 | Jan 21 | 434 | $$160 | 2 | SWEEP |
| PUT | $3 | Nov 20 | 7 | $$40 | 10 | SWEEP |
5 options trades shown · 80% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for RECURSION PHARMACEUTICALS, INC. (RXRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RXRX — frequently asked questions
What is RXRX stock price today?
RECURSION PHARMACEUTICALS, INC. (RXRX) is at $3.19, down 4.35% (-$0.15) at the Nov 13, 2026 close.
What is the RXRX price target?
The average analyst price target for RXRX is $8.00, ranging from $6 to $10, based on 5 analysts. Latest: Recursion Pharmaceuticals maintains on Oct 19, 2026.
What do analysts rate RXRX?
Analyst ratings for RXRX: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did RXRX beat earnings?
RXRX last reported on Aug 5, 2026: EPS -$0.25 vs -$0.24 expected — a miss of 4.2%.
Does RXRX pay a dividend?
RXRX does not currently pay a dividend.
How much debt does RXRX have?
RECURSION PHARMACEUTICALS, INC. reported $5M of debt and $546M of cash (Jun 30, 2026).
What are RXRX support and resistance levels?
Support: $2.92. Resistance: $3.44, $4.09, $4.51.
What are insiders doing with RXRX?
Insider activity: SELLING, 0 buys and 11 sells in the last 90 days.